- Reference code :
- wf457
- Published date :
-
14 November 2002
- Expired date :
-
01 April 2030
AstraZeneca PLC today announced that Åke Stavling will be leaving the Company on 31 January 2003. Åke Stavling is 58 and has been an Executive Director since April 1999. He played a key role in the integration of Astra and Zeneca following the merger in 1999 and since then has been responsible for Business Development. From 1993-1999 he was Executive Vice President and Chief Financial Officer of Astra AB and before that held senior positions at Atlas Copco and Ericsson.
Sir Tom McKillop, Chief Executive, AstraZeneca said ‘Åke Stavling has made an important contribution to the success of AstraZeneca and he leaves AstraZeneca with our thanks and best wishes for the future’.
Åke Stavling’s responsibilities for Business Development will transfer to John Patterson, Executive Vice President, AstraZeneca.
Further enquires to:
Media EnquiriesSteve Brown +44 (0)20 7304 5033 Emily Denney +44 (0)20 7304 5034 |
Investor RelationsMina Blair-Robinson +44 (0)20 7304 5084 Jonathan Hunt +44 (0)20 7304 5087 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
